CEBPZ and acute myeloid leukemia: While the classification retains much of the established diagnostic criteria for AML with PML::RARA, AML with RUNX1::RUNX1T1, and AML with CBF::MYH11, increased recognition of the importance of highly sensitive measurable residual disease (MRD) evaluation techniques, and the impact of concurrent molecular alterations reflect factors that impact patient management and therapeutic decisions in current practice.